---
title: "NovaBridge Biosciences 的股票在 HC Wainwright & Co. 将其目标价从 7 美元上调至 9 美元后，交易价格上涨"
description: "NovaBridge Biosciences 的股票在 HC Wainwright & Co. 将其目标价从 7 美元上调至 9 美元后，交易价格上涨"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275165768.md"
published_at: "2026-02-06T19:08:40.000Z"
---

# NovaBridge Biosciences 的股票在 HC Wainwright & Co. 将其目标价从 7 美元上调至 9 美元后，交易价格上涨

NovaBridge Biosciences 的股票在 HC Wainwright & Co. 将其目标价从 7 美元上调至 9 美元后，交易价格上涨。

### Related Stocks

- [NBP.US - NovaBridge Biosciences](https://longbridge.com/zh-CN/quote/NBP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| NovaBridge Biosciences Executive Begins Open-Market ADS Purchases | NovaBridge Biosciences announced that Dr. Sean Cao, Chief Business Development Officer, has started purchasing up to $10 | [Link](https://longbridge.com/zh-CN/news/273372934.md) |
| NovaBridge Biosciences (NASDAQ:NBP) Shares Could Be 41% Below Their Intrinsic Value Estimate | NovaBridge Biosciences (NASDAQ:NBP) is estimated to be 41% undervalued, with a fair value of US$6.72 compared to the cur | [Link](https://longbridge.com/zh-CN/news/271236079.md) |
| NovaBridge Reports Positive Phase 1b Results For Givastomig In Metastatic Gastric Cancer | NovaBridge Biosciences (NBP) announced positive Phase 1b results for its drug givastomig in combination with nivolumab a | [Link](https://longbridge.com/zh-CN/news/271659683.md) |
| I-Mab Files for Dual Primary Listing on Hong Kong Stock Exchange | I-Mab NovaBridge Biosciences has filed for a dual primary listing of its ordinary shares on the Hong Kong Stock Exchange | [Link](https://longbridge.com/zh-CN/news/263708668.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。